Evaluation of complete pathologic response

2014 ◽  
pp. 17-28
Author(s):  
Audrey Mailliez ◽  
Géraldine Lauridant-Philippin ◽  
Jacques M Bonneterre
Keyword(s):  
Pathologic Response ◽  
Complete Pathologic Response

scholarly journals CIC-DUX4 rearranged uterine cervix round-cell sarcoma exhibiting near-complete pathologic response following radiation and neoadjuvant chemotherapy: A case report

2021 ◽  
Vol 36 ◽  
pp. 100745
Author(s):  
Aline Cristini Vieira ◽  
Camila Bragança Xavier ◽  
Thiago Dieb Vieira ◽  
Filomena Marino Carvalho ◽  
Mariana Scaranti ◽  
...  
Keyword(s):  
Case Report ◽  
Neoadjuvant Chemotherapy ◽  
Uterine Cervix ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Round Cell ◽  
Cell Sarcoma

scholarly journals Pathologic validation of an yttrium-90 trans-arterial radioembolization dosimetry: a case report

2021 ◽  
Vol 2021 (4) ◽  
Author(s):  
Jacqueline B Baikovitz ◽  
Lindsay Thornton ◽  
Monica T Garcia-Buitrago ◽  
Alan S Livingstone ◽  
Matthew T Studenski ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Liver Resection ◽  
Pathologic Response ◽  
Clinical Scenario ◽  
Complete Pathologic Response ◽  
Pathological Findings ◽  
Rigorous Approach ◽  
Yttrium 90

Abstract Yttrium-90 (Y-90) trans-arterial radioembolization (TARE) is used in the management of unresectable hepatocellular carcinoma (HCC). During the last 5 years, dosimetry software has been developed to allow for a more rigorous approach of dose prescription in Y-90 TARE. We present here a case study of a 77-year-old woman diagnosed with HCC, who underwent a Y-90 TARE as a bridge procedure to liver resection. This clinical scenario represents a unique opportunity to illustrate the predictive value of dosimetric findings correlating dosimetry with pathological findings. In this case, Y-90 TARE dosimetry was predictive of treatment response in which the tumor received a mean dose of 156 Gy and demonstrated a complete pathologic response.

Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma

2016 ◽  
Vol 14 (1) ◽  
pp. e59-e65 ◽  
Author(s):  
Venkata K. Pokuri ◽  
Johar R. Syed ◽  
Zhengyu Yang ◽  
Erinn P. Field ◽  
Susanna Cyriac ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Bladder Carcinoma ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Muscle Invasive

855 OPTIMIZATION OF SURGICAL DELAY AFTER INDUCTION CHEMORADIATION FOR ESOPHAGEAL CANCER: 10 YEARS RETROSPECTIVE MULTI-CENTER STUDY

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Alexis Legault-Dupuis ◽  
Philippe Bouchard ◽  
Frederic Nicodème ◽  
Jean-Pierre Gagne ◽  
Serge Simard ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Disease Free Survival ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Free Survival ◽  
Surgical Delay ◽  
Multi Center Study ◽  
Disease Free ◽  
Center Study

Abstract   The treatment of esophageal cancer is in constant evolution. Most of the esophageal cancer receive induction chemoradiation therapy. Surgical delay has been studied but the optimal timing has not been clarified. Through the years, surgical delay has been modified by surgeons in our institutions, going from an average of 6 weeks delay to an average of 10 weeks delay. It is time to ask if this change has a real positive impact on our patient. Methods In this retrospective multi-center study, we combined data from two center in Quebec city that performs oncologic esophagectomy. The surgical delay went from 6 to 10 weeks around 2014. All surgeons changed their practice at that moment. We retrospectively analysed 5 years before and after the change of practice and created two cohorts of patients. Our primary outcome compared complete pathologic response rate. Our secondary outcomes were surgical complications, anastomotic leak, disease free survival and overall survival. Results Thirty-eight patients had surgery under 8 weeks (mean: 6 weeks) after their induction chemoradiation compared to 64 patients that had surgery after 8 weeks (mean: 10 weeks). There was no statistical significant difference between groups for the complete pathologic response (32% vs 25%, p = 0,16). Important complications were similar, with a rate of 24% vs 28% (p = 0,69). Anastomotic leaks were less frequent in the less than 8 weeks group, but no statistical significance was obtained (13% vs 27%, p = 0,14).No difference in the disease-free survival rate and overall survival rate was noted (DFS 40% vs 55% (p = 0,32), OS 38% vs 38% (p = 0,29)). Conclusion The treatment of esophageal cancer is in constant evolution, induction therapy and surgical technics involve over time. Surgical delay has no impact on complete pathologic response, complication and overall survival. There is no advantage to wait longer before surgery.

Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies

2020 ◽  
Vol 24 (10) ◽  
pp. 2336-2348
Author(s):  
Antolino Laura ◽  
Crovetto Anna ◽  
Matteo Cinquepalmi ◽  
Moschetta Giovanni ◽  
Mattei Maria Sole ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pancreatic Cancer ◽  
Prospective Studies ◽  
Pathologic Response ◽  
Complete Pathologic Response

Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?

2008 ◽  
Vol 26 (10) ◽  
pp. 1635-1641 ◽  
Author(s):  
René Adam ◽  
Dennis A. Wicherts ◽  
Robbert J. de Haas ◽  
Thomas Aloia ◽  
Francis Lévi ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Preoperative Chemotherapy ◽  
Predictive Factors ◽  
Colorectal Liver Metastases ◽  
Objective Response ◽  
Survival Rates ◽  
Postoperative Mortality ◽  
Pathologic Response ◽  
High Survival ◽  
Complete Pathologic Response

Purpose Complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherapy is of limited predictive value for complete pathologic response (CPR) and cure of the disease. The objective of this study was to determine predictive factors of CPR as well as its impact on survival. Patients and Methods From January 1985 to July 2006, 767 consecutive patients with CLM underwent liver resection after systemic chemotherapy. Patients with CPR were compared with patients without CPR. Results Twenty-nine of 767 (4%) patients had CPR, and none of these 29 patients had CCR. Patients with CPR (mean age, 54 years) had a mean number of 3.3 metastases at diagnosis (mean size, 29.3 mm). Objective response and stable disease were observed in 79% and 21% of cases, respectively. Postoperative mortality rate was 0%. After a median follow-up of 52.2 months (range, 1.1 to 193.0 months), overall 5-year survival was 76% for patients with CPR compared with 45% for patients without CPR (P = .004). Independent predictive factors for CPR were: age ≤ 60 years, size of metastases ≤ 3 cm at diagnosis, carcinoembryonic antigen (CEA) level at diagnosis ≤ 30 ng/mL, and objective response following chemotherapy. The probability of CPR ranged from 0.2% when all factors were absent to 30.9% when all were present. Conclusion CPR was observed in 4% of patients with CLM treated with preoperative chemotherapy. However, CPR may occur in almost one-third of objective responders age ≤ 60 years with metastases ≤ 3 cm and low CEA values. CPR is associated with uncommon high survival rates.

Sign in / Sign up

Export Citation Format

Share Document